van Hoogdalem, M.W.; Tanaka, R.; Abduljalil, K.; Johnson, T.N.; Wexelblatt, S.L.; Akinbi, H.T.; Vinks, A.A.; Mizuno, T.
Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling. Pharmaceutics 2024, 16, 375.
https://doi.org/10.3390/pharmaceutics16030375
AMA Style
van Hoogdalem MW, Tanaka R, Abduljalil K, Johnson TN, Wexelblatt SL, Akinbi HT, Vinks AA, Mizuno T.
Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling. Pharmaceutics. 2024; 16(3):375.
https://doi.org/10.3390/pharmaceutics16030375
Chicago/Turabian Style
van Hoogdalem, Matthijs W., Ryota Tanaka, Khaled Abduljalil, Trevor N. Johnson, Scott L. Wexelblatt, Henry T. Akinbi, Alexander A. Vinks, and Tomoyuki Mizuno.
2024. "Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling" Pharmaceutics 16, no. 3: 375.
https://doi.org/10.3390/pharmaceutics16030375
APA Style
van Hoogdalem, M. W., Tanaka, R., Abduljalil, K., Johnson, T. N., Wexelblatt, S. L., Akinbi, H. T., Vinks, A. A., & Mizuno, T.
(2024). Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling. Pharmaceutics, 16(3), 375.
https://doi.org/10.3390/pharmaceutics16030375
